2022

  • ALA-1000 Received notice of patent allowance from National Institute of Industrial Property Institute (INAPI), Chile on August 10, Application No. 624-2019 
  • ALA-1000 Received notice of patent allowance from  European Patent Office (EPO) on May 12 , Application No. 17850245.6.
  • ALA-1000 Received notice of patent allowance from Director de Invenciones y Nuevas Tecnologías INDECOPI on May 12, Application No. 000487-2019/DIN .
  • Alar-1000 Received notice of patent allowance from Intellectual Property Office of India on May 6, Application No. 201947006642.
  • Alar-1000 Received notice of patent allowance from Intellectual Property Office of Singapore (IPOS) on April 21, Application No. 11201901294Q.
  • Alar Announces Significant Progress on Developing long-acting Buprenorphine
    Injectable ALA-1000 on January 13.

2021

  • Alar-1000 Received notice of patent allowance from Directorate General of Intellectual Property (DGIP) of Indonesia on November 30 , Application No. P00201902139.
  • Alar Announce Results from ALA-1000 Single Ascending Dose Study in Opioid Dependent Patients on November 09.
  • ALA-1000 Received notice of patent allowance from Intellectual Property Office of Vietnam on October 29,  Application No. 1-2019-01258.
  • Successful End-of-Phase 2 Meeting with US FDA for ALA-1000 for the Treatment of Opioid Use Disorder on October 28.
  • ALA-1000 Receive notice of patent allowance from Taiwan Intellectual Property Office (TIPO) on September 3, Application No. 106131215. 
  • ALA-1000 Receive notice of patent allowance from South Africa-Companies and Intellectual Property Commission Department of Trade and Industry (CIPC) on August 25, Application No. 2019/00890. 
  • ALA-1000 Receive notice of patent allowance from Japan Patent Office (JPO) on August 3,  Application No. 特願2019-535434.
  • ALA-1000 Receive notice of patent allowance from Innovation, Science and Economic Development Canada (ISED) on May 10, 2021, Application No.3,033,046. 
  • ALA-1000 Receive notice of patent allowance from the IP New Zealand on April 30, 2021. Patent No. 750367
  • ALA-1000 Receive notice of allowance for patent registration from Korean Intellectual Property Office on April 16, 2021 (Application No. 10-2019-7009185). 
  • ALA-1000 Receive Decision of Grant from Federal Service for Intellectual Property (ROSPATENT) on April 12, 2021 (Application No. 2019102895). 

2020

  • Listed on Taipei Exchange Market in Taiwan on 23 September ,Traded on October 5
  • ALA-1000 Receive notice of patent allowance from the IP Australia.
  • ALA-3000 completes Pre-IND Meeting with US FDA
  • ALA-1000 Receive notice of patent allowance from the Mexican Institute of Industrial Property (IMPI)
  • Approved to be a public offering company on June 3.  Code : ( 6785 )
  • Receive notice of patent allowance from USPTO ( ALA-1000)
  • ALA-1000 was approved by  Ministry of Economic Affairs : A+ Industrial Innovation R&D Program(fast track)

2019

  • Approved by the Ministry of Economic Affairs as a Biotech Pharmaceutical  company

  • ALA-1000  received US FDA IND approval.

  • Approved to locate in Central Science Park

2017

  • ALA-1000 was approved by Ministry of Economic Affairs :A+ Industrial Innovation R&D Program-Industrial Technology Foresight Research Program

2016

  • Alar Pharmaceuticals Inc was founded

Add Your Heading Text Here